Are you Dr. Malamut?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Blvd
Suite Acp #533
Chester, PA 19013Phone+1 610-874-1184Fax+1 610-874-4258
Summary
- Dr. Richard Malamut, MD is a board certified neurologist in Chester, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
- University of Pennsylvania Health SystemResidency, Neurology, 1986 - 1989
- University of Pennsylvania Health SystemInternship, Internal Medicine, 1985 - 1986
- Drexel University College of MedicineClass of 1985
Certifications & Licensure
- PA State Medical License 1986 - 2026
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Start of enrollment: 2004 Sep 08
Publications & Presentations
PubMed
- 1 citationsEffect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.Mary Bond, Laura Rabinovich-Guilatt, Sally Selim, Mona Darwish, William Tracewell
Clinical Drug Investigation. 2017-09-25 - 2 citationsEvaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Ab...Martin E. Hale, Thomas R Zimmerman, Yuju Ma, Richard Malamut
Pain Practice. 2017-02-01 - 7 citationsSix-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potentialMartin E. Hale, Yuju Ma, Richard Malamut
Journal of Opioid Management. 2016-03-01
Press Mentions
- Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain MedicineOctober 26th, 2020
- Collegium Appoints Richard Malamut, M.D., as Chief Medical OfficerApril 2nd, 2019
- Avanir Pharmaceuticals to Present Data on NUEDEXTA® and ONZETRA® Xsail® at American Academy of Neurology (AAN) 2017 Annual MeetingApril 19th, 2017
- Join now to see all